Belotero® Intense Lidocaine for Lip Filler
Study Summary
This trial studied the safety and effectiveness of a lip filler, Belotero Intense Lidocaine (BIL), to plump up thin lips.
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2014 Phase 4 trial • 40 Patients • NCT01602692Awards & Highlights
Trial Design
Find a site
Who is running the clinical trial?
Media Library
Frequently Asked Questions
Are there any vacancies available in this medical study?
"According to clinicaltrials.gov, this trial is actively seeking participants at present. The original post was made on March 3rd 2023 and the listing has been updated most recently on June 3rd 2023."
Is this study seeking elderly volunteers aged 75 and above?
"According to the stated criteria, individuals between 21 and 65 years of age are eligible for this particular clinical trial."
What are the qualifying criteria for taking part in this clinical trial?
"This clinical trial is accepting patients from 21 to 65 years old with lip fillers. In total, 220 participants are required for the study."
What is the highest reported figure of participants in this experiment?
"Confirmed. According to the details hosted on clinicaltrials.gov, this medical experiment is currently enrolling participants and was first posted on March 3rd 2023 with an updated being published on March 6th 2023. It requires 220 individuals from 1 centre of care for completion."
What is the intended outcome of this medical experiment?
"This clinical trial's primary outcome is the Responder Rates at V3, as evaluated through the MLFAS. Secondary outcomes include subjects' GAIS Scores, changes from Baseline in Rasch-transformed Score of the FACE-Q Satisfaction with Lips and Number of Subjects With Related Serious or Related Delayed-onset Treatment Emergent Adverse Events (TEAEs). These assessments span a period starting on Day 1 to Week 8 post last injection, up to 12 Weeks (V3)."